[go: up one dir, main page]

NO970567L - Anvendelse av ketoconazol og relaterte substanser i medikamenter for behandling av type II diabetes - Google Patents

Anvendelse av ketoconazol og relaterte substanser i medikamenter for behandling av type II diabetes

Info

Publication number
NO970567L
NO970567L NO970567A NO970567A NO970567L NO 970567 L NO970567 L NO 970567L NO 970567 A NO970567 A NO 970567A NO 970567 A NO970567 A NO 970567A NO 970567 L NO970567 L NO 970567L
Authority
NO
Norway
Prior art keywords
ketoconazole
diabetes
drugs
type
treatment
Prior art date
Application number
NO970567A
Other languages
English (en)
Other versions
NO970567D0 (no
NO314616B1 (no
Inventor
Per Maerin
Original Assignee
Metabolic Syndrome I Gbg Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Metabolic Syndrome I Gbg Ab filed Critical Metabolic Syndrome I Gbg Ab
Publication of NO970567D0 publication Critical patent/NO970567D0/no
Publication of NO970567L publication Critical patent/NO970567L/no
Publication of NO314616B1 publication Critical patent/NO314616B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
    • B65B—MACHINES, APPARATUS OR DEVICES FOR, OR METHODS OF, PACKAGING ARTICLES OR MATERIALS; UNPACKING
    • B65B1/00—Packaging fluent solid material, e.g. powders, granular or loose fibrous material, loose masses of small articles, in individual containers or receptacles, e.g. bags, sacks, boxes, cartons, cans, or jars
    • B65B1/04—Methods of, or means for, filling the material into the containers or receptacles
    • B65B1/08—Methods of, or means for, filling the material into the containers or receptacles by vibratory feeders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Mechanical Engineering (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NO19970567A 1994-08-09 1997-02-07 Anvendelse av ketoconazol og relaterte substanser i medikamenter for behandling av type II diabetes NO314616B1 (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/SE1994/000729 WO1996004912A1 (en) 1994-08-09 1994-08-09 Use of ketoconazole and related substances in medicaments for treatment of type ii diabetes

Publications (3)

Publication Number Publication Date
NO970567D0 NO970567D0 (no) 1997-02-07
NO970567L true NO970567L (no) 1997-02-07
NO314616B1 NO314616B1 (no) 2003-04-22

Family

ID=20393155

Family Applications (1)

Application Number Title Priority Date Filing Date
NO19970567A NO314616B1 (no) 1994-08-09 1997-02-07 Anvendelse av ketoconazol og relaterte substanser i medikamenter for behandling av type II diabetes

Country Status (14)

Country Link
US (2) US5849740A (no)
EP (2) EP1360960A1 (no)
JP (1) JP3825469B2 (no)
KR (1) KR100422162B1 (no)
AT (1) ATE244009T1 (no)
CA (1) CA2196174C (no)
CZ (1) CZ285290B6 (no)
DE (1) DE69432905T2 (no)
DK (1) DK0779810T3 (no)
ES (1) ES2202326T3 (no)
NO (1) NO314616B1 (no)
PT (1) PT779810E (no)
SI (1) SI0779810T1 (no)
WO (1) WO1996004912A1 (no)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1360960A1 (en) * 1994-08-09 2003-11-12 Cortendo AB Use of ketoconazole and related substances in medicaments for treatment of type II diabetes
US6642236B1 (en) * 1998-12-14 2003-11-04 Cortendo Ab Methods for prophylactic treatment of cardiovascular disease with inhibitor of cortisol synthesis
SE9700642D0 (sv) 1997-02-24 1997-02-24 Kronvall Stefan Med Ab Medel och sätt för förebyggande och behandling av det metabola syndromet
GB0001449D0 (en) * 2000-01-21 2000-03-08 Cortendo Ab Compositions
SE0001899D0 (sv) 2000-05-22 2000-05-22 Pharmacia & Upjohn Ab New compounds
GB0118300D0 (en) * 2001-07-26 2001-09-19 Cortendo Ab Formulations
WO2003055975A2 (en) * 2001-08-23 2003-07-10 New England Biolabs, Inc. A method for engineering strand-specific, sequence-specific, dna-nicking enzymes
EA200400707A1 (ru) 2001-11-22 2004-10-28 Биовитрум Аб Ингибиторы 11-бета-гидроксистероиддегидрогеназы типа 1
US20080200453A1 (en) 2002-07-29 2008-08-21 Cincotta Anthony H Methods of treating metabolic syndrome using dopamine receptor agonists
US20040220190A1 (en) * 2002-07-29 2004-11-04 Cincotta Anthony H. Methods of treating metabolic syndrome using dopamine receptor agonists
US9655865B2 (en) 2002-07-29 2017-05-23 Veroscience, Llc Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US8821915B2 (en) 2002-08-09 2014-09-02 Veroscience, Llc Therapeutic process for the treatment of the metabolic syndrome and associated metabolic disorders
EP1533619B1 (en) 2003-11-20 2009-04-29 F. Hoffmann-Roche AG Specific markers for metabolic syndrome
US8137994B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US8137993B2 (en) * 2004-03-25 2012-03-20 Veroscience Llc Methods of identifying responders to dopamine agonist therapy and treating metabolic conditions thereof
US20050215558A1 (en) * 2004-03-25 2005-09-29 Cincotta Anthony H Methods of identifying responders to dopamine agonist therapy
MX2007008331A (es) * 2005-01-10 2008-01-14 Cortendo Invest Ab Publ Metodos y composiciones para el tratamiento de diabetes, sindrome metabolico y otras condiciones.
CA2637000A1 (en) * 2006-01-10 2007-07-19 Diobex, Inc. Methods and compositions for treating prostate cancer, benign prostatic hypertrophy, polycystic ovary syndrome and other conditions
JP2006206605A (ja) * 2006-03-29 2006-08-10 Metabolic Syndrome I Goeteborg Ab 代謝性症候群の治療薬
EP1886695A1 (en) * 2006-06-27 2008-02-13 Speedel Experimenta AG Pharmaceutical combination of an aldosterone synthase inhibitor and a glucocorticoid receptor antagonist or a cortisol synthesis inhibitor or a corticotropin releasing factor antagonist
EP2076265A4 (en) 2006-10-02 2010-09-22 Cortendo Invest Ab KETOCONAZOLE ENANTIOMER IN HUMANS
US9352025B2 (en) 2009-06-05 2016-05-31 Veroscience Llc Combination of dopamine agonists plus first phase insulin secretagogues for the treatment of metabolic disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432176A (en) * 1988-11-29 1995-07-11 The John Hopkins University Method of retarding the progression of chronic renal failure
US5175144A (en) * 1988-11-29 1992-12-29 The Johns Hopkins University Method of retarding the progression of chronic renal failure
EP1360960A1 (en) * 1994-08-09 2003-11-12 Cortendo AB Use of ketoconazole and related substances in medicaments for treatment of type II diabetes
US5591736A (en) * 1995-07-03 1997-01-07 The Johns Hopkins University Method of retarding the progression of chronic renal failure

Also Published As

Publication number Publication date
AU695011B2 (en) 1998-08-06
DE69432905D1 (de) 2003-08-07
WO1996004912A1 (en) 1996-02-22
DK0779810T3 (da) 2003-10-20
JPH10510241A (ja) 1998-10-06
KR100422162B1 (ko) 2004-07-07
AU7711894A (en) 1996-03-07
CZ36097A3 (en) 1997-06-11
US5849740A (en) 1998-12-15
CA2196174A1 (en) 1996-02-22
JP3825469B2 (ja) 2006-09-27
ATE244009T1 (de) 2003-07-15
NO970567D0 (no) 1997-02-07
EP0779810A1 (en) 1997-06-25
EP0779810B8 (en) 2003-09-17
ES2202326T3 (es) 2004-04-01
CZ285290B6 (cs) 1999-06-16
CA2196174C (en) 2005-03-01
NO314616B1 (no) 2003-04-22
EP0779810B1 (en) 2003-07-02
EP1360960A1 (en) 2003-11-12
PT779810E (pt) 2003-11-28
US6166017A (en) 2000-12-26
DE69432905T2 (de) 2004-05-27
KR970704440A (ko) 1997-09-06
SI0779810T1 (en) 2003-12-31

Similar Documents

Publication Publication Date Title
NO970567L (no) Anvendelse av ketoconazol og relaterte substanser i medikamenter for behandling av type II diabetes
NO995932D0 (no) Anvendelse av tiazolidindion-derivater i behandling av polycystiske ovariesyndrom og svangerskapsdiabetes
NO20006194L (no) Farmasöytisk sammensetning for behandling av funksjonell dyspepsi og/eller irriterbar innvollssyndrom og ny anvendelse av substanser deri
TR199901172T2 (xx) Yeni ikame edilmi� pirazol t�revleri.
KR970706002A (ko) 남성의 상대적 안드로겐 결핍증 치료를 위한 약제의 제조에 있어서 아로마타제 억제제의 용도(Use of Aromatase Inhibitors in the Preparation of a Drug for Treating a Relative Androgen Deficiency in Men)
ATE186219T1 (de) Kombination von antihormonale und bindende moleküle zur krebsbehandlung
EA199800104A1 (ru) Способ лечения диабета
CY1107752T1 (el) Xρηση των εξενδινων και αγωνιστων τους για τη θεραπεια του σακχαρωδους διαβητη της κυησης
NO20010982L (no) Fremgangsmåte for å administrere insulinotropiske peptider
DE60042598D1 (de) Medikamente zur behandlung des syndroms der chronishen ermüdung, das mit fibromyalgie und reizdarm assoziert ist.
BR0308904A (pt) Método de tratamento de gastroparesia, e, uso de um composto de glp-1
MXPA02007099A (es) Compuestos de tiazola, imidazola y oxazola y tratamientos de desordenes asociados con la maduracion de la proteina.
IL143569A0 (en) A combination of fbpase inhibitors and insulin sensitizers for the treatment of diabetes
NO20015932D0 (no) Fremgangsmåte til å behandle diabetes
EA199800317A1 (ru) СЕЛЕКТИВНЫЕ β-АДРЕНЕРГИЧЕСКИЕ АГОНИСТЫ
TR200100348T2 (tr) Gen tedavisi teknikleri
JP2003528919A5 (no)
WO2004087076A3 (en) Methods for inhibiting adipogenesis and for treating type 2 diabetes
DE60037032D1 (de) Anwendung von pdt zur inhibierung von hyperplasie der intima
ATE337005T1 (de) Nagellack enthaltend tazaroten und verwendung dessen zur behandlung und/oder zur prävention von psoriasis
NO894008D0 (no) Trekonserveringsmiddel og fremgangsmaate for behandling avtre med samme.
AU6102801A (en) Method of preventing or treating diabetes
WO1999013894A3 (en) Use of ifn-alpha and amantadine for the treatment of chronic hepatitis c
ATE288263T1 (de) Verwendung von n-oleoylethanolamin zur behandlung der schuppenflechte (psoriasis)
ATE271878T1 (de) Verwendung von protein h als zytostattischer wirkstoff

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees